Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease

In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD). We investigated whether plasma copeptin levels, a mar...

詳細記述

保存先:
書誌詳細
出版年:Kidney Int
主要な著者: Gansevoort, Ron T., van Gastel, Maatje D.A., Chapman, Arlene B., Blais, Jaime D., Czerwiec, Frank S., Higashihara, Eiji, Lee, Jennifer, Ouyang, John, Perrone, Ronald D., Stade, Katrin, Torres, Vicente E., Devuyst, Olivier
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6640141/
https://ncbi.nlm.nih.gov/pubmed/30898339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.kint.2018.11.044
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料